Spyre Therapeutics
SYRE
94 hedge funds and large institutions have $275M invested in Spyre Therapeutics in 2020 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 10 closing their positions.
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
8% more funds holding
Funds holding: 87 → 94 (+7)
0.07% more ownership
Funds ownership: 3.41% → 3.48% (+0.07%)
22% less capital invested
Capital invested by funds: $352M → $275M (-$76.7M)
26% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 31
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$8.41M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$3.04M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.77M |
| 4 |
Axa
Paris,
France
|
+$2.26M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$7.63M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.42M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.56M |
| 4 |
Renaissance Technologies
New York
|
-$1.53M |
| 5 |
Millennium Management
New York
|
-$954K |
SYRE Hedge Fund Activity: Q3 2020 in Review
94 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q3 2020, worth a combined $275M — down 22% from $352M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new SYRE positions and 10 closed out — a net gain of 7 holders — while 23 added to existing stakes and 31 trimmed.
The largest buyer was Pictet Asset Management (UK), opening a new position worth an estimated $8.41M. The largest seller was Deerfield Management, exiting entirely with an estimated $7.63M sold.
- 94 institutional investors held Spyre Therapeutics (SYRE) as of Q3 2020, up from 87 in Q2 2020.
- Funds reported $275M of Spyre Therapeutics stock for Q3 2020, down 22% quarter-over-quarter.
- 17 funds opened new Spyre Therapeutics positions in Q3 2020 and 10 closed out, a net change of +7 holders.
- The largest Spyre Therapeutics buyer in Q3 2020 was Pictet Asset Management (UK), an estimated $8.41M added.
- The largest Spyre Therapeutics seller in Q3 2020 was Deerfield Management, an estimated $7.63M sold.
Based on aggregated 13F filings for Q3 2020.